Abstracts accepted for the 2010 ASCO Annual Meeting


Twenty EORTC abstracts have been accepted for presentation at the 2010 ASCO Annual meeting to be held 4-8 June in Chicago, Illinois. A listing of these abstracts is given below.

Oral Abstract Session

EORTC Genito-Urinary Tract Cancer Group

Abstract ID LBA4519

Randomized phase II/III trial comparing gemcitabine/carboplatin (GC) and methotrexate/carboplatin/vinblastine (M-CAVI) in patients (pts) with advanced urothelial cancer (UC) “unfit” for cisplatin based chemotherapy (CHT): phase III results of EORTC study 30986. M. De Santis, J. Bellmunt, G. Mead, J.M. Kerst, M. Leahy, G. Daugaard, T. Gil, P. Maroto, S. Marreaud, and R. Sylvester.

EORTC Melanoma Group

Abstract ID 50930

Randomized phase III trial comparing post-operative adjuvant ganglioside GM2-KLH/QS-21 vaccination vs observation in stage II (T3-T4N0M0) melanoma: Final results of study EORTC 18961. A. M. Eggermont, S. Suciu, P. Rutkowski, J. Marsden, A. Testori, P. Corrie, S. Aamdal, P. A. Ascierto, P. Patel, and A. Spatz.

EORTC Genito-Urinary Tract Cancer Group

Abstract ID 4512

A randomized phase III study comparing standard dose BEP with sequential high-dose Cisplatin, Etoposide, Ifosfamide (VIP) plus stem cell support in males with poor prognosis germ cell cancer (GCC). An intergroup study of EORTC, GTCSG, and Gruppo Germinal (EORTC 30974). G. Daugaard,  I. Skoneczna, N. Aas, R. de Wit, M. De Santis, H. Dumez, S. Marreaud, L. Collette, C. Bokemeyer, and H.J. Schmoll.

EORTC Gastrointestinal Tract Cancer Group

Abstract ID 3526

Final results of the EORTC Intergroup Randomized study 40004 (CLOCC) evaluating the benefit of Radiofrequency Ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM). T. Ruers, C. Punt, F. van Coevorden, J.P. Pierie, I. Borel Rinkes, J. Ledermann, G. J. Poston, W. Bechstein, M. Lentz, M. Mauer, and B. Nordlinger.

EORTC Breast Cancer Group

Abstract ID LBA503

Phase III breast cancer trial (EORTC 10994/BIG 00-01) assessing the value of p53 using a functional assay to predict for sensitivity to a taxane versus non taxane primary chemotherapy regimen: final analysis. Hervé Bonnefoi, Jan Bogaerts, Martine Piccart, Louis Mauriac, Pierre Fumoleau, Jacek Jassem, Véronique Becette, David Cameron, Jonas Bergh and Richard Iggo.

Poster Discussion Session

EORTC Quality of Life Group

Abstract ID 9146

Health related quality of life and clinical data comprise a valid prognostic tool to aid in survival prediction in a subgroup of metastatic cancer patients. C. Quinten, F. Martinelli, J. Vercauteren, E. Greimel, B. Reeve, C. Cleeland, M. Taphoorn, J. Weis, J. Schmucker-von Koch, and A. Bottomley.

EORTC Soft Tissue and Bone Sarcoma Group

Abstract ID 10074

First line chemotherapy for malignant peripheral nerve sheath tumour (MPNST) versus other histologic soft tissue sarcoma (STS) subtypes and as a prognostic factor for MPNST: An EORTC soft tissue and bone sarcoma group (STBSG) study. J. R. Kroep, M. Ouali, H. Gelderblom, A. Le Cesne, T. J. A. Dekker, M. M. Van Glabbeke, P. Hohenberger, and P. C. W. Hogendoorn.

EORTC Lung Cancer Group

Abstract ID 7518

A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021- ILCP 01/03). R. M. Gaafar, V. Surmont, G. Scagliotti, R. Van Klaveren, D. Papamichael, J. Welch, B. Hasan, V. Torri, and J. P. Van Meerbeeck.

EORTC Brain Tumor and Radiation Oncology Groups

Abstract ID 9306

Quality-of-life results of an EORTC phase III randomized trial of adjuvant whole brain radiotherapy versus observation after radio surgery or surgical resection of 1-3 cerebral metastases of solid tumors. R. Soffietti, R. P. Mueller, M. U. Abacioglu, S. Villa, F. Fauchon, B. Baumert, L. Fariselli, G. Tridello, M. Kocher, and A. Bottomley.

EORTC Soft Tissue and Bone Sarcoma Group

Abstract ID 10040

Soluble factors (SF) associated with efficacy and toxicity of pazopanib (PZB) in advanced soft tissue sarcoma (STS) patients (pts); An EORTC-STBSG study. S. Sleijfer, M. M. Van Glabbeke, C. Lamers, H. Burger, J. Y. Blay, A. L. Cesne, M. R. Scurr, A. N. Bartlett-Pandite, S. Marreaud, and P. Hohenberger.

EORTC Soft Tissue and Bone Sarcoma Group

Abstract ID 10051

Outcome of patients (pts) with PDGFRAD842V mutant gastrointestinal stromal tumor (GIST) treated with imatinib (IM) for advanced disease. P. Biron, P.A. Cassier, E. Fumagalli, A. Blesius, M. Debiec-Rychter, A. Adenis, J. Verweij, P. Hohenberger, J.Y. Blay, and P.G. Casali.

EORTC Soft Tissue and Bone Sarcoma Group

Abstract ID 10031

Activity of eribulin mesylate (E7389) in patients with soft tissue sarcoma (STS): Phase II studies of the European Organization for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (EORTC 62052). P. Schoffski, I. L. Ray-Coquard, A. Cioffi, N. Bin Bui, S. Bauer, J. T. Hartmann, R. Sciot, J. Wanders, D. Druyts, and P. Hohenberger.

EORTC Soft Tissue and Bone Sarcoma Group

Abstract ID 10037

Brostallicin versus doxorubicin as first line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An EORTC Soft Tissue and Bone Sarcoma Group randomized phase II study. H. Gelderblom, J.Y. Blay, B. M. Seddon, M. Leahy, I.L. Ray-Coquard, A. De brauwer, E. Veyt, S.D. Weitman, P.C.W. Hogendoorn, and P. Hohenberger.

EORTC Breast Cancer Group

Abstract ID TPS116

LAPATAX: A randomized phase II trial of FEC-docetaxel combined with lapatinib and/or trastuzumab as neo-adjuvant therapy of HER2 positive breast cancer: EORTC 10054 trial. D.A. Cameron, S. Marreaud, K. Zaman, A. Bodmer, J.Y. Pierga, E. Brain, C. Veyret, J.M. Bartlett, J. Bogaerts, and H.R. Bonnefoi.

EORTC Gastrointestinal Tract Cancer Group

Abstract ID 3591

Lessons from PETACC 2 – no prognostic impact of KRAS-/BRAF-status in stage III colon cancer treated with adjuvant 5-FU monotherapy. D.E. Aust, M.P. Lutz, M. Mauer, I. Popov, G.B. Baretton, L. Bedenne, A. Carrato, and C.H. Köhne.

General Poster Session

EORTC Quality of Life Group

Abstract ID 9075

The association between clinical, socio-demographic and logistic-administrative factors and adherence to completing health-related quality of life questionnaires. J. Vercauteren, J. Maringwa, C. Coens, C. Quinten, C. Gotay, J. Ringash, M. King, D. Osoba, H. Flechtner and A. Bottomley on behalf of the EORTC.

EORTC Lung Cancer Group

Abstract ID 7052

Randomized phase II study (EORTC 08062) of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED SCLC). M.E.R O’Brien, J. Jassem, P. Lorigan, L. Bosquee, E. Marshall, F. Bustin, J. Stigt, A.C. Dingemans, B. Hasan, and J.P. Van Meerbeeck.

EORTC Gastrointestinal Tract Cancer Group

Abstract ID TPS205

Lapatinib in Combination with ECF/X in EGFR1 or HER2 Overexpressing First-Line Metastatic Gastric Cancer (GC): A Phase II Randomized Placebo Controlled Trial (EORTC 40071). Arnaud Roth, Markus Moehler, Murielle Mauer, A Schad, Matthias Karrasch, Michel Praet, Michael Lim, Ash Das-Gupta, and Manfred P. Lutz.

EORTC Gastrointestinal Tract Cancer Group

Abstract ID 3544

Predictive factors for the effect of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC phase III study 40983). H. Sorbye, M. Mauer, T. Gruenberger, B. Glimelius, G. J. Poston, P. M. Schlag, P. Rougier, J. N. Primrose, E. T. Walpole, B. Nordlinger.

Publication Only

EORTC New Drug Development Group

Abstract ID 53018

Vascular effects of the vascular targeting agent NGR-hTNF in patients (pts) with advanced solid cancer: a dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) EORTC study. H.W.M. van Laarhoven, I.M.E. Desar, J.J.A. van Asten, W. Fiedler, S. Marreaud, J.N.H. Timmer-Bonte, E.G.W. ter Voert, A. Lambiase, A. Heerschap, and C.M.L. van Herpen.

 Stéphanie Vandergooten
John Bean


Find us

Avenue Emmanuel Mounier, 83/11
Brussels 1200

Contact us

Follow us